By Fineline Cube 
China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals. Under the agreement, Sagent has obtained exclusive commercialization rights to certain complex injectable products from Qilu for the US market. This collaboration spans multiple high-demand therapeutic areas.
Market Potential
The product portfolio involved in the deal is estimated to have a total potential market size exceeding USD 4.5 billion. Both companies anticipate that this initiative will significantly enhance access to critical injectable medications, reduce treatment costs, and strengthen supply chain resilience.
Sagent’s Capabilities
Sagent, a leading US supplier of generic and specialty pharmaceuticals, offers a diverse portfolio covering over 100 therapeutic categories, dosage forms, and packaging configurations, including vials, syringes, and premixed bags. By leveraging its global partner network, rapid development capabilities, advanced manufacturing processes, and innovative drug delivery technologies, Sagent continues to expand its product offerings to address evolving patient needs.-Fineline Info & Tech